S&P 500   5,088.80
DOW   39,131.53
QQQ   436.78
Warren Buffett uses his annual letter to warn about Wall Street and recount Berkshire's successes
The perfect AI stock under $10 (Ad)
A collection of the insights Warren Buffett offered in his annual letter Saturday
West Africa bloc lifts coup sanctions on Niger in a new push for dialogue to resolve tensions
The perfect AI stock under $10 (Ad)
Macron booed by French farmers who blame him for not doing enough to support agriculture
West Africa's ECOWAS bloc says it's lifting sanctions imposed on Niger over last year’s coup in a new push for dialogue
Free Stock Analysis Report: See The True Value of Any Stock (Ad)
MILAN FASHION PHOTOS: Ferragamo, Dolce&Gabbana conceal and reveal, balance transparency with cover
Tax-free status of movie, music and games traded online is on table as WTO nations meet in Abu Dhabi
S&P 500   5,088.80
DOW   39,131.53
QQQ   436.78
Warren Buffett uses his annual letter to warn about Wall Street and recount Berkshire's successes
The perfect AI stock under $10 (Ad)
A collection of the insights Warren Buffett offered in his annual letter Saturday
West Africa bloc lifts coup sanctions on Niger in a new push for dialogue to resolve tensions
The perfect AI stock under $10 (Ad)
Macron booed by French farmers who blame him for not doing enough to support agriculture
West Africa's ECOWAS bloc says it's lifting sanctions imposed on Niger over last year’s coup in a new push for dialogue
Free Stock Analysis Report: See The True Value of Any Stock (Ad)
MILAN FASHION PHOTOS: Ferragamo, Dolce&Gabbana conceal and reveal, balance transparency with cover
Tax-free status of movie, music and games traded online is on table as WTO nations meet in Abu Dhabi
S&P 500   5,088.80
DOW   39,131.53
QQQ   436.78
Warren Buffett uses his annual letter to warn about Wall Street and recount Berkshire's successes
The perfect AI stock under $10 (Ad)
A collection of the insights Warren Buffett offered in his annual letter Saturday
West Africa bloc lifts coup sanctions on Niger in a new push for dialogue to resolve tensions
The perfect AI stock under $10 (Ad)
Macron booed by French farmers who blame him for not doing enough to support agriculture
West Africa's ECOWAS bloc says it's lifting sanctions imposed on Niger over last year’s coup in a new push for dialogue
Free Stock Analysis Report: See The True Value of Any Stock (Ad)
MILAN FASHION PHOTOS: Ferragamo, Dolce&Gabbana conceal and reveal, balance transparency with cover
Tax-free status of movie, music and games traded online is on table as WTO nations meet in Abu Dhabi
S&P 500   5,088.80
DOW   39,131.53
QQQ   436.78
Warren Buffett uses his annual letter to warn about Wall Street and recount Berkshire's successes
The perfect AI stock under $10 (Ad)
A collection of the insights Warren Buffett offered in his annual letter Saturday
West Africa bloc lifts coup sanctions on Niger in a new push for dialogue to resolve tensions
The perfect AI stock under $10 (Ad)
Macron booed by French farmers who blame him for not doing enough to support agriculture
West Africa's ECOWAS bloc says it's lifting sanctions imposed on Niger over last year’s coup in a new push for dialogue
Free Stock Analysis Report: See The True Value of Any Stock (Ad)
MILAN FASHION PHOTOS: Ferragamo, Dolce&Gabbana conceal and reveal, balance transparency with cover
Tax-free status of movie, music and games traded online is on table as WTO nations meet in Abu Dhabi
NASDAQ:TXG

10x Genomics (TXG) Stock Price, News & Analysis

$44.98
-0.58 (-1.27%)
(As of 02/23/2024 ET)
Today's Range
$44.47
$45.74
50-Day Range
$41.56
$57.55
52-Week Range
$33.79
$63.57
Volume
705,686 shs
Average Volume
1.32 million shs
Market Capitalization
$5.32 billion
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
$62.44

10x Genomics MarketRank™ Stock Analysis

Analyst Rating
Moderate Buy
2.89 Rating Score
Upside/​Downside
38.8% Upside
$62.44 Price Target
Short Interest
Bearish
5.63% of Shares Sold Short
Dividend Strength
N/A
Sustainability
-0.73
Upright™ Environmental Score
News Sentiment
0.46mentions of 10x Genomics in the last 14 days
Based on 6 Articles This Week
Insider Trading
Selling Shares
$340,550 Sold Last Quarter
Proj. Earnings Growth
Growing
From ($1.48) to ($0.74) Per Share

Overall MarketRank

New Rank-Based ScoringMarketRank is calculated by averaging available category scores (with extra weight given to analysis and valuation), then ranking the company's weighted average against that of other companies.

4.68 out of 5 stars

Medical Sector

64th out of 940 stocks

Analytical Instruments Industry

3rd out of 28 stocks


TXG stock logo

About 10x Genomics Stock (NASDAQ:TXG)

10x Genomics, Inc., a life science technology company, develops and sells instruments, consumables, and software for analyzing biological systems in North America, Europe, the Middle East, Africa, China, and the Asia Pacific. The company provides chromium and chromium connect instruments, microfluidic chips, slides, reagents, and other consumables products. Its single cell solutions runs on its chromium instruments, which include single cell gene expression for measuring gene activity on a cell-by-cell basis; single cell immune profiling for measuring the activity of immune cells and their targets; single cell Assay for Transposase Accessible Chromati (ATAC) for measuring epigenetics comprising the physical organization of DNA; and single cell multiome ATAC + gene expression for measuring the genetic activity and epigenetic programming in the same cells across tens of thousands of cells in a single experiment. The company also provides visium spatial gene expression solution for measuring spatial gene expression patterns across a single tissue sample or gene expression and protein co-detection when combined with immunofluorescence. It serves various academic, government, biopharmaceutical, biotechnology, and other institutions. The company was formerly known as 10X Technologies, Inc. and changed its name to 10x Genomics, Inc. in November 2014. 10x Genomics, Inc. was incorporated in 2012 and is headquartered in Pleasanton, California.

TXG Stock Price History

TXG Stock News Headlines

Free Stock Analysis Report: See The True Value of Any Stock
Get a full report that tells you what a stock is really worth, how safe the stock is, and if the timing is right to buy the stock. Plus a definitive Buy, Sell, Hold recommendation.
10x Genomics (NASDAQ:TXG) PT Lowered to $63.00 at Stifel Nicolaus
Free Stock Analysis Report: See The True Value of Any Stock
Get a full report that tells you what a stock is really worth, how safe the stock is, and if the timing is right to buy the stock. Plus a definitive Buy, Sell, Hold recommendation.
Q4 2023 10X Genomics Inc Earnings Call
10x Genomics: Q4 Earnings Insights
10x Genomics Q4 2023 Earnings Preview
Preview: 10x Genomics's Earnings
10X Genomics Inc (TXG)
See More Headlines
Receive TXG Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for 10x Genomics and its competitors with MarketBeat's FREE daily newsletter.

Company Calendar

Last Earnings
2/15/2024
Today
2/25/2024
Next Earnings (Estimated)
5/01/2024
Fiscal Year End
12/31/2024

Industry, Sector and Symbol

Sector
Medical
Industry
Analytical instruments
Sub-Industry
N/A
Current Symbol
NASDAQ:TXG
Fax
N/A
Employees
1,243
Year Founded
N/A

Price Target and Rating

Average Stock Price Target
$62.44
High Stock Price Target
$75.00
Low Stock Price Target
$54.00
Potential Upside/Downside
+38.8%
Consensus Rating
Moderate Buy
Rating Score (0-4)
2.89
Research Coverage
9 Analysts

Profitability

Net Income
$-255,100,000.00
Pretax Margin
-40.21%

Debt

Sales & Book Value

Annual Sales
$618.73 million
Book Value
$6.27 per share

Miscellaneous

Free Float
105,620,000
Market Cap
$5.32 billion
Optionable
Optionable
Beta
1.92
7 AI Stocks to Invest In: An Introduction to AI Investing For Self-Directed Investors Cover

As the AI market heats up, investors who have a vision for artificial intelligence have the potential to see real returns. Learn about the industry as a whole as well as seven companies that are getting work done with the power of AI.

Get This Free Report

Key Executives

  • Dr. Serge Saxonov Ph.D. (Age 47)
    Co-Founder, CEO & Director
    Comp: $837.68k
  • Dr. Benjamin J. Hindson Ph.D. (Age 49)
    Co-Founder, President, Chief Scientific Officer & Director
    Comp: $615.96k
  • Mr. Justin J. McAnearMr. Justin J. McAnear (Age 48)
    Chief Financial Officer
    Comp: $535.91k
  • Mr. Eric S. Whitaker Esq. (Age 57)
    Chief Legal Officer
    Comp: $558.97k
  • Mr. Michael Schnall-Levin
    Founding Scientist & CTO
  • Ms. Cassie Corneau
    Manager of Investor Relations and Strategic Finance
  • Ms. Rebecca Port
    Chief People Officer
  • Mr. James Bryant
    Director of Legal
  • Mr. Nikhil Rao
    Director of Product Management
  • Mr. Florian Baumgartner
    Senior Product Manager














TXG Stock Analysis - Frequently Asked Questions

Should I buy or sell 10x Genomics stock right now?

9 Wall Street analysts have issued "buy," "hold," and "sell" ratings for 10x Genomics in the last year. There are currently 1 hold rating and 8 buy ratings for the stock. The consensus among Wall Street analysts is that investors should "moderate buy" TXG shares.
View TXG analyst ratings
or view top-rated stocks.

What is 10x Genomics' stock price target for 2024?

9 Wall Street analysts have issued twelve-month price targets for 10x Genomics' shares. Their TXG share price targets range from $54.00 to $75.00. On average, they anticipate the company's share price to reach $62.44 in the next twelve months. This suggests a possible upside of 38.8% from the stock's current price.
View analysts price targets for TXG
or view top-rated stocks among Wall Street analysts.

How have TXG shares performed in 2024?

10x Genomics' stock was trading at $55.96 at the start of the year. Since then, TXG shares have decreased by 19.6% and is now trading at $44.98.
View the best growth stocks for 2024 here
.

Are investors shorting 10x Genomics?

10x Genomics saw a increase in short interest during the month of January. As of January 31st, there was short interest totaling 6,660,000 shares, an increase of 16.4% from the January 15th total of 5,720,000 shares. Based on an average daily trading volume, of 1,160,000 shares, the short-interest ratio is presently 5.7 days.
View 10x Genomics' Short Interest
.

When is 10x Genomics' next earnings date?

The company is scheduled to release its next quarterly earnings announcement on Wednesday, May 1st 2024.
View our TXG earnings forecast
.

How were 10x Genomics' earnings last quarter?

10x Genomics, Inc. (NASDAQ:TXG) released its quarterly earnings data on Thursday, February, 15th. The company reported ($0.41) EPS for the quarter, missing analysts' consensus estimates of ($0.36) by $0.05. The company earned $183.98 million during the quarter, compared to analysts' expectations of $182.73 million. 10x Genomics had a negative net margin of 41.17% and a negative trailing twelve-month return on equity of 28.82%. The firm's revenue was up 17.8% on a year-over-year basis. During the same period in the previous year, the firm posted ($0.15) EPS.

What guidance has 10x Genomics issued on next quarter's earnings?

10x Genomics updated its FY 2024 earnings guidance on Friday, February, 16th. The company provided EPS guidance of for the period. The company issued revenue guidance of $670.0 million-$690.0 million, compared to the consensus revenue estimate of $702.1 million.

What is Serge Saxonov's approval rating as 10x Genomics' CEO?

25 employees have rated 10x Genomics Chief Executive Officer Serge Saxonov on Glassdoor.com. Serge Saxonov has an approval rating of 100% among the company's employees. This puts Serge Saxonov in the top 10% of approval ratings compared to other CEOs of publicly-traded companies.

When did 10x Genomics IPO?

(TXG) raised $297 million in an initial public offering (IPO) on Thursday, September 12th 2019. The company issued 9,000,000 shares at $31.00-$35.00 per share. J.P. Morgan, Goldman Sachs and BofA Merrill Lynch served as the underwriters for the IPO and Cowen was co-manager.

Who are 10x Genomics' major shareholders?

10x Genomics' stock is owned by many different institutional and retail investors. Top institutional shareholders include Vanguard Group Inc. (7.62%), Baillie Gifford & Co. (6.70%), ARK Investment Management LLC (3.42%), Sands Capital Management LLC (3.04%), Brown Capital Management LLC (2.98%) and Price T Rowe Associates Inc. MD (2.63%). Insiders that own company stock include Benjamin J Hindson, Benjamin J Hindson, Bradford Crutchfield, James Wilbur, John R Stuelpnagel, John R Stuelpnagel, Justin J Mcanear, Justin J Mcanear, Mathai Mammen, Serge Saxonov and Sridhar Kosaraju.
View institutional ownership trends
.

How do I buy shares of 10x Genomics?

Shares of TXG stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.
Compare Top Brokerages Here.

This page (NASDAQ:TXG) was last updated on 2/25/2024 by MarketBeat.com Staff